Article
Plasminogen activator inhibitor-1 polymorphisms (-844 G>A and HindIII C>G) in systemic lupus erythematosus: association with clinical variables.
Clinical and experimental medicine - 1 Mar 2011
Padilla-Gutiérrez Jorge Ramón, Palafox-Sánchez Claudia Azucena, Valle Yeminia, Orozco-Barocio Gerardo, Oregón-Romero Edith, Vázquez-Del Mercado Mónica, Rangel-Villalobos Héctor, Llamas-Covarrubias Mara Anaís, Muñoz-Valle José Francisco
Abstract excerpt
Systemic lupus erythematosus (SLE) is a systemic autoimmune disease characterized by the presence of autoantibodies against nuclear autoantigens as well as cytoplasmic and circulating proteins. Recent studies have demonstrated mechanisms responsible for modulation of the immune response by the plasminogen activator inhibitor-1 (PAI-1). Furthermore, the endogenous PAI-1 has shown to promote a Th2 immune response....
Topics
- Adolescent
- Adult
- Aged
- Case-Control Studies
- Female
- Gene Frequency
- Humans
- Lupus Erythematosus, Systemic
- Male
- Mexico
- Middle Aged
- Plasminogen Activator Inhibitor 1